The Immunotherapy Revolution in Cancer Care
For most of the 20th century, cancer treatment relied on three pillars: surgery, radiation, and chemotherapy. Each works by directly attacking cancer cells — but each also damages healthy tissue, leading to the well-known toxicities of traditional cancer treatment.
Immunotherapy represents a fundamentally different approach: rather than attacking cancer directly, it harnesses and amplifies the body's own immune system to recognize and destroy cancer cells. This paradigm shift began in earnest in the early 2010s and has since produced some of the most remarkable outcomes in oncology history.
How the Immune System Fights Cancer
The immune system continuously surveys the body for abnormal cells. Natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) can recognize cancer-specific antigens and mount an anti-tumor response. However, cancer cells have evolved multiple mechanisms to evade immune destruction:
Immunotherapy works by overcoming these evasion mechanisms.
Checkpoint Inhibitors: Releasing the Brakes
The most successful immunotherapy approach to date involves blocking immune checkpoints — molecular brakes that prevent excessive immune activation.
#
PD-1/PD-L1 Inhibitors
PD-1 (programmed death-1) is a receptor on T cells that, when bound by PD-L1 on cancer cells, inactivates the T cell. By blocking PD-1 or PD-L1, these medicines restore T cell activity against tumors.Approved PD-1 inhibitors:
Approved PD-L1 inhibitors:
#
CTLA-4 Inhibitors
CTLA-4 is another checkpoint that dampens T cell activation in lymph nodes. Blocking it allows more T cells to activate and attack tumors.CAR-T Cell Therapy: Engineering Immune Killers
Chimeric Antigen Receptor T cell (CAR-T) therapy is one of the most complex and revolutionary treatments in oncology. The process:
1. T cells are extracted from the patient's blood via leukapheresis 2. Cells are engineered in a laboratory to express a synthetic receptor (CAR) targeting a specific cancer antigen 3. Cells are expanded to hundreds of millions 4. Patient receives lymphodepleting chemotherapy to make room for CAR-T cells 5. Engineered cells are infused back — they proliferate and attack cancer cells expressing the target antigen
Approved CAR-T therapies (2024):
Cancer Vaccines
Therapeutic vaccines treat existing cancer by training the immune system to recognize tumor antigens.
Preventive vaccines prevent cancer caused by infectious agents:
mRNA cancer vaccines — the most promising frontier. Following COVID-19 mRNA vaccine success, personalized mRNA vaccines that encode a patient's unique tumor neoantigens are in Phase III trials for melanoma (Moderna + Merck) with striking early results.
Immune-Related Adverse Events (irAEs)
Unlike chemotherapy toxicity (nausea, hair loss, myelosuppression), immunotherapy causes immune-related adverse events — autoimmune-like inflammation affecting various organ systems:
Management involves corticosteroids, and often permanent discontinuation of immunotherapy for severe events (Grades 3-4).
Frequently Asked Questions
Who is eligible for immunotherapy?
Eligibility depends on cancer type, specific biomarkers (PD-L1 expression, MSI-H/dMMR status, tumor mutational burden), prior treatment history, and performance status. Many cancers now have FDA-approved immunotherapy options. Biomarker testing guides which patients will respond best.
What is PD-L1 testing?
PD-L1 expression on tumor cells is a biomarker tested by immunohistochemistry on tumor biopsies. Higher PD-L1 expression generally predicts better response to PD-1/PD-L1 inhibitors, though it is an imperfect predictor. PD-L1 testing is required before first-line pembrolizumab in NSCLC.
Can immunotherapy cause the cancer to grow faster?
In approximately 10-15% of patients, tumors grow paradoxically faster after immunotherapy begins — called hyperprogression. This appears more common with PD-1 inhibitors in patients with certain genomic alterations. Close monitoring after initiation is essential.
How long does immunotherapy treatment last?
Duration varies by medicine and response. Some protocols treat for 2 years regardless of response; others continue until progression or unacceptable toxicity. A minority of patients achieve durable complete responses lasting years after stopping treatment — possibly representing functional cures.
Medicines Mentioned in This Article
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider before making any medication decisions.